# lung adenocarcinoma (LUAD) - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 15270
- Completion tokens: 5114
- Reasoning tokens: 0
- Total tokens: 20384
- API requests reported: 2
- Elapsed seconds: 1104.282
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: OpenAI

---
## Data-quality warning and interpretation scope

The survival results are technically suspicious and should **not** be interpreted as calibrated effect estimates. Among 100 unique genes, 96 are risk-associated and 4 protective-associated, while many rows have exactly `P=0`, `FDR=0`, and HR values at or near `5.1847055e+21` or `1.9287498e-22`. This pattern is compatible with complete or quasi-complete separation, zero/near-zero variance, sparse expression, censoring-related instability, or an encoding/modeling problem. The ledger also reports 263 retained rows and 2 duplicated genes/probes, including a direction conflict for `Y_RNA`.

Accordingly, the **signs and reported values are preserved as uploaded**, but the extreme HR magnitudes and zero P values should be treated as unreliable until the survival model is rerun and audited. The biologic interpretation below is therefore **exploratory**, based on the more moderate HR estimates and on external annotations. No independent-cohort survival statistic was supplied; **external statistical validation was not performed**.

## 1. Overall biological interpretation

The dataset is dominated by risk-associated survival signals, but the predominance of extreme HRs among pseudogenes, small RNAs, Y-chromosome-related transcripts, uncharacterized loci, and unmapped Ensembl identifiers strongly suggests that technical or compositional factors may be contributing substantially.

Among the more interpretable genes, the pattern is compatible with several interacting LUAD-relevant features:

- **Wnt-related signaling and epithelial-state regulation**, represented most directly by risk-associated `DKK1` (HR=1.4752957, FDR=3.5473347e-07), together with pathway annotations involving Wnt regulation and planar cell polarity.
- **Cell adhesion, cytoskeletal remodeling, and migratory behavior**, represented by risk-associated `ITGB1-DT`, `RHOF`, `KRT6A`, and `RGS20`.
- **Cell-surface glycosylation**, represented by risk-associated `FUT4`, with retrieved pathway records involving mannose-type O-glycan and glycosphingolipid biosynthesis.
- **Transcriptional or lineage-state signals**, including risk-associated `PITX3`, `VAX1`, and `TLE1`.
- A small, internally discordant **protective-associated group**, particularly `RBMXP1` (HR=0.21180097, FDR=1.597144e-17), `CRNDE` (HR=0.71599561, FDR=0.00010281398), and `CMAHP` (HR=0.70553839, FDR=0.00057718765).

These findings support a working hypothesis of poor-OS association with altered epithelial identity, adhesion/motility, signaling, and glycosylation. They do **not** establish that any of these genes causes LUAD progression.

## 2. Core biological programs

### Program 1: Wnt-related signaling and epithelial-state regulation

- **Association:** Predominantly risk-associated.
- **Supporting genes:** `DKK1` (HR=1.4752957), with contextual support from `CREG2`, `ITGB1-DT`, `KRT6A`, and `RHOF`.
- **Standardized pathways:**  
  - GO: Regulation of Wnt signaling pathway (GO:0030111)  
  - GO: Positive regulation of Wnt signaling pathway  
  - GO: Planar cell polarity pathway (GO:2000096)  
  - KEGG: Wnt signaling pathway
- **Interpretation:** `DKK1` is the clearest direct statistical anchor for this program. The retrieved ontology/pathway batch repeatedly connected selected genes to Wnt regulation, planar cell polarity, and cell-junction disassembly. This combination is biologically consistent with altered epithelial organization and invasive cell behavior.
- **Evidence strength:** **Supported hypothesis.** Direct survival evidence exists for `DKK1`; pathway evidence is contextual and was not recomputed as a new enrichment statistic.
- **Limitations:** `DKK1` can have context-dependent effects on Wnt signaling, and pathway annotation does not prove pathway activation in these tumors. The available results do not provide Wnt target-gene activity scores, mutation status, protein abundance, or independent LUAD replication.

### Program 2: Cell adhesion, actin remodeling, and migration

- **Association:** Risk-associated.
- **Supporting genes:** `ITGB1-DT` (HR=1.3024374), `RHOF` (HR=1.4033848), `KRT6A` (HR=1.390124), `RGS20` (HR=1.3520645), and `LDLRAD3` (HR=1.4198041).
- **Standardized pathways:**  
  - GO: Cell junction disassembly (GO:0150146)  
  - GO: Actin filament organization  
  - GO: Cell migration  
  - GO: Regulation of small GTPase-mediated signal transduction
- **Interpretation:** `RHOF` is annotated in actin organization, cell migration, and small-GTPase signaling. `RGS20` is associated with G-protein signaling, while `KRT6A` is compatible with epithelial remodeling or a basal-like epithelial state. The group collectively suggests a survival-associated tissue state involving altered cell-cell contacts and cytoskeletal dynamics.
- **Evidence strength:** **Supported hypothesis**, because several genes have concordant risk direction and compatible functional annotations. The direct statistical evidence remains prognostic association only.
- **External context:** STRING records connect `RHOF` with `ACTN1` and `ARHGAP1`; these should be regarded as database-supported functional associations unless the specific source demonstrates direct physical binding. A PubMed record reports that high `RhoF` predicted worse overall survival in non-M3 acute myeloid leukemia (PMID: 34405015), which is disease-external and therefore only supportive of plausibility, not LUAD validation.
- **Limitations:** This pattern could reflect tumor purity, squamous/basal-like epithelial admixture, stromal content, or generalized tissue injury rather than a tumor-cell-intrinsic migration program.

### Program 3: Glycosylation and cell-surface carbohydrate remodeling

- **Association:** Risk-associated.
- **Supporting genes:** `FUT4` (HR=1.4025353), with contextual contributions from `DKK1`, `KRT6A`, `CREG2`, and `LDLRAD3`.
- **Standardized pathways:**  
  - KEGG: Mannose type O-glycan biosynthesis  
  - KEGG: Glycosphingolipid biosynthesis
- **Interpretation:** `FUT4` is a fucosyltransferase and provides the most direct mechanistic anchor. Altered glycosylation can influence receptor organization, cell adhesion, immune recognition, and metastatic behavior. The retrieved network records link `FUT4` with `B3GNT3` and `B4GALT1`; this is best described as pathway or functional-network association, not necessarily direct physical interaction.
- **Evidence strength:** **Exploratory to supported hypothesis.** The statistical association for `FUT4` is strong within this dataset, and the pathway annotation is biologically coherent, but no formal pathway enrichment statistic or glycomic measurement was supplied.
- **Limitations:** The pathway records may reflect broad annotation overlap, and the data do not show whether glycan structures, fucosylation activity, or glycosyltransferase protein levels actually differ.

### Program 4: Transcriptional and lineage-state regulation

- **Association:** Risk-associated for `PITX3`, `VAX1`, and `TLE1`; protective-associated for `CRNDE` is directionally discordant with this group.
- **Supporting genes:** `PITX3` (HR=1.4290801), `VAX1` (HR=1.3347835), `TLE1` (HR=1.4844831), and `CRNDE` (HR=0.71599561).
- **Standardized pathways:** No single standardized pathway can be assigned confidently from the supplied evidence. These genes are more appropriately considered a candidate transcriptional/lineage-state module.
- **Interpretation:** The concordant risk associations of `PITX3`, `VAX1`, and `TLE1` may indicate a tumor-cell state or differentiation program associated with outcome. However, the inclusion of `CRNDE` as protective-associated argues against treating this as a unified validated program.
- **Evidence strength:** **Exploratory hypothesis.**
- **Limitations:** There is insufficient evidence to infer a direct regulatory circuit among these genes. Transcription-factor annotation, co-expression, and literature co-occurrence would not by themselves demonstrate direct regulation.

### Program 5: Sex-chromosome, small-RNA, pseudogene, and unannotated transcript signal

- **Association:** Mostly extreme risk-associated or protective-associated values.
- **Supporting genes:** Examples include `RBMY1F`, `RBMY2AP`, `TTTY4C`, `RNU6-78P`, `Y_RNA`, `MIR509-1`, numerous pseudogenes, and unmapped Ensembl identifiers.
- **Standardized pathways:** No reliable biologic pathway assignment is justified.
- **Interpretation:** This is primarily a **data-quality and composition signal**, not a disease mechanism. Strong associations for Y-linked transcripts may reflect sex composition; pseudogenes and small RNAs may reflect annotation, low counts, mapping ambiguity, or sparse expression.
- **Evidence strength:** **Insufficient evidence for a mechanistic interpretation.**
- **Validation priority:** Recheck read mapping, feature annotation, expression distributions, sex balance, library size, zero counts, and proportional-hazards assumptions before pursuing these loci biologically.

## 3. Key genes and candidate interaction modules

| Candidate | Uploaded association | Program relevance | Relationship type and interpretation |
|---|---:|---|---|
| `DKK1` | Risk-associated; HR=1.4752957, FDR=3.5473347e-07 | Wnt-related signaling and epithelial organization | Wnt pathway co-membership and regulatory plausibility; no direct physical interaction with the other selected genes was established |
| `RHOF` | Risk-associated; HR=1.4033848, FDR=0.00039972073 | Actin remodeling, migration, small-GTPase signaling | STRING associations with `ACTN1` and `ARHGAP1` are functional/network evidence; direct physical interaction is not established by the supplied record |
| `RGS20` | Risk-associated; HR=1.3520645, FDR=0.00057926328 | G-protein and signal-transduction regulation | STRING records support associations with `GNAZ`, `GNB5`, `GNAI2`, and `GNAQ`; these are database-supported protein-network relationships, not proven causal relationships in LUAD |
| `KRT6A` | Risk-associated; HR=1.390124, FDR=0.00027842294 | Epithelial remodeling and possibly basal-like state | Likely pathway/state co-membership with adhesion and epithelial-remodeling genes; no direct interaction inferred |
| `FUT4` | Risk-associated; HR=1.4025353, FDR=0.00029348425 | Glycosylation and cell-surface remodeling | Functional/pathway association with `B3GNT3` and `B4GALT1`; not evidence of direct binding |
| `ITGB1-DT` | Risk-associated; HR=1.3024374, FDR=0.00014780674 | Adhesion and epithelial-state regulation | Literature reports ITGB1-DT/ARNTL2 as a possible LUAD biomarker in a bioinformatics and experimental study (PMID: 34906142); this is external biologic context, not an independent survival statistic supplied here |
| `TLE1` | Risk-associated; HR=1.4844831, FDR=2.4568017e-05 | Transcriptional or lineage-state regulation | Candidate transcriptional-state marker; direct regulation of the other selected genes is not demonstrated |
| `PITX3` | Risk-associated; HR=1.4290801, FDR=3.4900114e-11 | Candidate differentiation or lineage program | Transcription-factor-related hypothesis; no LUAD-specific causal mechanism is established by the supplied evidence |
| `RBMXP1` | Protective-associated; HR=0.21180097, FDR=1.597144e-17 | Protective-associated transcript signal | Strong uploaded association but biologic interpretation is uncertain because it is a pseudogene; insufficient evidence for a protective mechanism |
| `CRNDE` | Protective-associated; HR=0.71599561, FDR=0.00010281398 | Potential noncoding regulatory or state marker | Direction is discordant with most selected genes; co-expression or regulatory relationships require direct testing and cannot be inferred from the survival table |

The most coherent candidate module is therefore `DKK1–RHOF/RGS20–KRT6A–FUT4–ITGB1-DT`, representing Wnt/epithelial-state, cytoskeletal, signaling, and glycosylation features. This is a **putative functional module**, not a demonstrated physical complex.

## 4. Validation priorities

### 1. Refit and audit the survival model

- **Class:** Confounding or composition check
- **Why prioritize:** The extreme HRs and exact zero P/FDR values make model instability the primary concern.
- **Current evidence:** 96/100 genes are risk-associated; many HRs are `5.1847055e+21`, and the ledger reports duplicate rows and a direction conflict.
- **Next step:** Reconstruct the expression matrix and survival inputs; inspect counts, variance, missingness, event numbers, censoring, feature mapping, sex-linked features, and proportional-hazards assumptions. Refit using penalized Cox regression or Firth correction, with pre-specified filtering and nested cross-validation.
- **Conclusion:** The current global prognostic pattern is an **exploratory, technically unstable finding**, not established evidence.

### 2. Validate a Wnt–epithelial-state program centered on `DKK1`

- **Class:** Mechanistic hypothesis
- **Why prioritize:** `DKK1` has a moderate, interpretable risk HR, and the retrieved annotations repeatedly implicate Wnt regulation, planar cell polarity, and junctional remodeling.
- **Current evidence:** `DKK1` HR=1.4752957; pathway records include GO:0030111 and KEGG Wnt signaling.
- **External evidence:** Pathway annotations support plausibility, but no independent LUAD survival statistic was supplied. Annotation recurrence is not replication.
- **Next step:** Test Wnt target activity and epithelial-state scores in an independent LUAD cohort; measure DKK1 protein and β-catenin/TCF target activity by immunohistochemistry, RNA profiling, or functional perturbation.
- **Conclusion:** **Supported hypothesis**, not established causality.

### 3. Test the adhesion–cytoskeleton–migration module

- **Class:** Interaction / network hypothesis
- **Why prioritize:** `RHOF`, `RGS20`, `KRT6A`, `ITGB1-DT`, and `LDLRAD3` are all risk-associated with compatible cellular functions.
- **Current evidence:** HRs range from 1.2898228 for `RHCG` to 1.4198041 for `LDLRAD3`, with statistically significant uploaded FDR values; `RHOF` has GO annotations for actin organization and migration.
- **External evidence:** STRING provides functional associations for `RHOF` with `ACTN1` and `ARHGAP1`, while `RGS20` is connected to G-protein signaling partners. These records do not establish direct physical interactions or LUAD-specific causality.
- **Next step:** Perform co-expression and module analysis in independent tumors, followed by protein-level co-localization and perturbation experiments measuring migration, invasion, and junction integrity.
- **Conclusion:** **Supported hypothesis** at the program level; individual interactions remain exploratory.

### 4. Validate `FUT4` and tumor glycosylation

- **Class:** Biomarker
- **Why prioritize:** `FUT4` has a moderate risk association and is more mechanistically interpretable than many unannotated high-HR transcripts.
- **Current evidence:** HR=1.4025353, FDR=0.00029348425; contextual records connect the selected genes to O-glycan and glycosphingolipid biosynthesis.
- **External evidence:** Pathway and network annotations support plausibility, but no external cohort statistic or direct glycomic evidence was supplied.
- **Next step:** Replicate the association in an independent LUAD cohort and quantify FUT4 protein, fucosylated surface glycans, and relevant glycan structures in tumor cells; adjust for stage, sex, purity, and treatment.
- **Conclusion:** **Exploratory biomarker hypothesis**.

### 5. Evaluate tumor purity, sex composition, and cell-type composition

- **Class:** Confounding or composition check
- **Why prioritize:** Many extreme signals are Y-linked, pseudogenic, small-RNA, or uncharacterized, and these can track sex, tumor purity, RNA quality, or cell mixture.
- **Current evidence:** Examples include `RBMY1F`, `RBMY2AP`, `TTTY4C`, `Y_RNA`, multiple pseudogenes, and unmapped Ensembl features. The protective-associated `RBMXP1` is also a pseudogene, making mechanistic interpretation especially uncertain.
- **External evidence:** Tissue-expression and annotation databases provide context but do not distinguish tumor-intrinsic from composition-derived expression in this cohort.
- **Next step:** Compare associations after adjustment for sex, purity, immune/stromal estimates, stage, smoking history, treatment, and batch; repeat analyses separately in male and female tumors and in purified or single-cell datasets.
- **Conclusion:** **High-priority confounding hypothesis**; currently unresolved.

## 5. Evidence grounding

- **Direct cohort evidence:** The uploaded survival table and ledger are the only direct statistical evidence. They support the reported directions and FDR values, but the extreme estimates are technically unreliable.
- **Pathway/ontology evidence:** Retrieved records support Wnt regulation, planar cell polarity, cell-junction disassembly, glycan biosynthesis, actin organization, and G-protein signaling. These records explain biologic plausibility but are not new enrichment P values.
- **Network evidence:** STRING and related records support functional associations involving `RHOF`, `RGS20`, and `FUT4`. The relationship type is source-dependent and should not be upgraded to direct physical interaction without experimental evidence.
- **Disease and tissue evidence:** LUAD relevance is strongest for `ITGB1-DT` because the supplied literature includes a LUAD biomarker study (PMID: 34906142). The RhoF survival article is from acute myeloid leukemia (PMID: 34405015), so it is not disease-specific replication.
- **Literature evidence:** Literature records support plausibility for selected genes, but the supplied evidence pack does not provide independent-cohort HRs that can be compared with the uploaded estimates.
- **Therapeutic evidence:** The presence of drug or clinical-trial records for some genes is not evidence that targeting them is effective in LUAD. No therapeutic conclusion is established here.
- **Independence:** Pathway, network, tissue, and literature sources may share annotations, prediction models, or publications. Their convergence is therefore supportive context, not independent validation.

## 6. Major limitations and alternative explanations

1. **Separation and numerical instability:** Exact zero P values, zero FDR values, and astronomical HRs may arise from sparse features or perfect outcome separation. Penalized or Firth Cox models and raw-data inspection are required.

2. **Cellular composition and tumor purity:** `KRT6A`, adhesion genes, Y-linked transcripts, and uncharacterized RNAs may reflect differences in malignant, stromal, immune, or sex-specific cell composition. Purity adjustment, deconvolution, matched histology, and single-cell or spatial profiling can test this.

3. **Clinical confounding:** Stage, treatment exposure, smoking history, age, sex, and performance status are not supplied. Their omission can produce prognostic associations that are not independent of disease severity.

4. **Annotation and mapping problems:** Pseudogenes, lncRNAs, small RNAs, duplicated probes, and unmapped Ensembl identifiers are vulnerable to cross-mapping and low-count artifacts. Reanalysis using stable gene identifiers, unique probes, minimum-expression filters, and read-level quality control is necessary.

5. **Association-versus-causation ambiguity:** Even reproducible survival associations may represent biomarkers of an aggressive tumor state rather than drivers. Functional perturbation, rescue experiments, and prospective validation are needed before assigning causal or therapeutic significance.

Overall, the most defensible interpretation is an **exploratory LUAD prognostic signature potentially involving Wnt/epithelial-state regulation, adhesion–cytoskeletal remodeling, and glycosylation**, but the current statistical output must first be technically revalidated before these programs or individual genes can be considered reliable prognostic biomarkers or therapeutic targets.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=40, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
